Literature DB >> 1009684

Binding of phytohaemagglutinin to serum substances and inhibition of lymphocyte transformation in Hodgkin's disease.

P L Amlot, A Unger.   

Abstract

Serum from eleven of fifty-four patients with Hodgkin's disease inhibited phytohaemagglutinin (PHA) stimulation of both autologous and homologous lymphocytes. The inhibitory effect resided in the macromolecular fraction of these sera. PHA was shown to bind to serum substances in inhibitory sera and the degree of PHA binding in the macromolecular fraction correlated directly with the extent of inhibition.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1009684      PMCID: PMC1540991     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Effect of phytohaemagglutinin on human serum and cell proteins.

Authors:  L BECKMAN
Journal:  Nature       Date:  1962-08-11       Impact factor: 49.962

3.  Studies on pregnancy-associated globulin.

Authors:  C H Horne; A L McLay; H B Tavadia; I Carmichael; A C Mallinson; A A Laiwah; M A Thomas; R N MacSween
Journal:  Clin Exp Immunol       Date:  1973-04       Impact factor: 4.330

4.  The effects of human serum fractions on phytohemagglutinin- and concanavalin A-stimulated human lymphocyte cultures.

Authors:  P S Chase
Journal:  Cell Immunol       Date:  1972-12       Impact factor: 4.868

5.  Reduced lymphocyte transformation in breast cancer.

Authors:  M G Whittaker; K Rees; C G Clark
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

6.  Lymphocyte response to P.H.A. in patients with non-lymphoid tumours.

Authors:  D B Garrioch; R A Good; R A Gatti
Journal:  Lancet       Date:  1970-03-21       Impact factor: 79.321

7.  Reduced lymphocyte transformation due to a plasma factor in patients with active syphilis.

Authors:  G M Levene; J L Turk; D J Wright; A G Grimble
Journal:  Lancet       Date:  1969-08-02       Impact factor: 79.321

8.  Impaired in vitro lymphocyte transformation in Hodgkin's disease.

Authors:  E M Hersh; J J Oppenheim
Journal:  N Engl J Med       Date:  1965-11-04       Impact factor: 91.245

9.  Lymphocyte response to phytohemagglutinin in Hodgkin's disease, lymphatic leukemia and lymphosarcoma.

Authors:  S Trubowitz; B Masek; A Del Rosario
Journal:  Cancer       Date:  1966-12       Impact factor: 6.860

10.  Recent immunological findins in Hodgkin's disease.

Authors:  V Grifoni
Journal:  Tumori       Date:  1973 Sep-Oct
View more
  7 in total

1.  Circulating immune complexes after repeated halothane anaesthesia.

Authors:  B D Williams; N White; P L Amlot; J Slaney; P A Toseland
Journal:  Br Med J       Date:  1977-07-16

2.  In vitro modulation of lymphocyte responses to phytohaemagglutinin by plasma in mother and baby at the time of birth. Increased lymphocyte responses in babies of mothers with lepromatous leprosy.

Authors:  G Bjune; E Duncan; R S Barnetson; R Melsom
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

3.  Correlation between immune complexes and prognostic factors in Hodgkin's disease.

Authors:  P L Amlot; B Pussell; J M Slaney; B D Williams
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

4.  Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease.

Authors:  T A Shiftan; A P Caviles; J Mendelsohn
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

5.  Antibody-dependent and phytohaemagglutinin-induced lymphocyte cytotoxicity in systemic lupus erythematosus.

Authors:  J K Wright; P Hughes; K Gelsthorpe; A M Ward; N R Rowell
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

6.  Absence of IgG lymphocytotoxins in untreated Hodgkin's disease (HD) patients.

Authors:  D B Jones; E V Elliott; S V Payne; D H Wright
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

7.  Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.

Authors:  M J Embleton; J H Ransom; M B McIllmurray; W G Reeves
Journal:  Br J Cancer       Date:  1978-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.